RALLYBIO CORPORATION Income (Loss) from Equity Method Investments
RALLYBIO CORPORATION (RLYB) reported Income (Loss) from Equity Method Investments of $0 for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-26
- RALLYBIO CORPORATION income (loss) from equity method investments for the quarter ending 2026-06-30 was $0.00.
- RALLYBIO CORPORATION income (loss) from equity method investments for the quarter ending 2026-03-31 was $0.00.
- RALLYBIO CORPORATION income (loss) from equity method investments for the quarter ending 2025-12-31 was $0.00.
- RALLYBIO CORPORATION income (loss) from equity method investments for the quarter ending 2025-09-30 was $0.00.
- RALLYBIO CORPORATION income (loss) from equity method investments for fiscal 2023 was -$2.04M.
- RALLYBIO CORPORATION income (loss) from equity method investments for fiscal 2022 was -$1.07M.
- RALLYBIO CORPORATION income (loss) from equity method investments for fiscal 2021 was -$1.50M.
- RALLYBIO CORPORATION income (loss) from equity method investments for fiscal 2020 was -$1.52M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 S-4/A · filed 2026-08-26 | $0.00 S-4/A · filed 2026-08-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-26 | $0.00 derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $0.00 S-4 · filed 2026-07-15 | $0.00 derived: sum of 2 quarters · filed 2026-08-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-26 | -$287.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $0.00 derived: sum of 2 quarters · filed 2026-08-26 | -$287.00K derived: sum of 3 quarters · filed 2026-08-26 | -$874.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | -$287.00K derived: sum of 2 quarters · filed 2026-08-26 | -$874.00K 10-Q · filed 2025-11-06 | -$1.30M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | -$287.00K S-4/A · filed 2026-08-26 | -$874.00K S-4/A · filed 2026-08-26 | -$1.30M derived: sum of 3 quarters · filed 2026-08-26 | -$1.94M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | -$587.00K S-4 · filed 2026-07-15 | -$1.02M derived: sum of 2 quarters · filed 2026-08-26 | -$1.65M derived: sum of 3 quarters · filed 2026-08-26 | -$2.14M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$430.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$1.07M derived: sum of 2 quarters · filed 2026-08-26 | -$1.55M derived: sum of 3 quarters · filed 2026-08-26 | -$2.24M S-4/A · filed 2026-08-26 |
| 2024-09-30 | -$637.00K 10-Q · filed 2025-11-06 | -$1.12M derived: sum of 2 quarters · filed 2025-11-06 | -$1.81M 10-Q · filed 2025-11-06 | -$2.42M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$487.00K 10-Q · filed 2025-08-07 | -$1.17M 10-Q · filed 2025-08-07 | -$1.78M derived: sum of 3 quarters · filed 2025-08-07 | -$2.43M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$685.00K 10-Q · filed 2025-05-08 | -$1.30M derived: sum of 2 quarters · filed 2025-05-08 | -$1.95M derived: sum of 3 quarters · filed 2025-05-08 | -$2.16M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$613.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$1.26M derived: sum of 2 quarters · filed 2025-03-13 | -$1.48M derived: sum of 3 quarters · filed 2025-03-13 | -$2.04M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$648.00K 10-Q · filed 2024-11-07 | -$865.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.43M 10-Q · filed 2024-11-07 | -$1.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$217.00K 10-Q · filed 2024-08-08 | -$780.00K 10-Q · filed 2024-08-08 | -$994.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$563.00K 10-Q · filed 2024-05-09 | -$777.00K derived: sum of 2 quarters · filed 2024-05-09 | -$910.00K derived: sum of 3 quarters · filed 2024-05-09 | -$1.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$347.00K derived: sum of 2 quarters · filed 2024-03-12 | -$685.00K derived: sum of 3 quarters · filed 2024-03-12 | -$1.07M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$133.00K 10-Q · filed 2023-11-09 | -$471.00K derived: sum of 2 quarters · filed 2023-11-09 | -$861.00K 10-Q · filed 2023-11-09 | -$1.08M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$338.00K 10-Q · filed 2023-08-08 | -$728.00K 10-Q · filed 2023-08-08 | -$951.00K derived: sum of 3 quarters · filed 2023-08-08 | -$1.28M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$390.00K 10-Q · filed 2023-05-09 | -$613.00K derived: sum of 2 quarters · filed 2023-05-09 | -$945.00K derived: sum of 3 quarters · filed 2023-05-09 | -$1.41M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$555.00K derived: sum of 2 quarters · filed 2023-03-06 | -$1.02M derived: sum of 3 quarters · filed 2023-03-06 | -$1.50M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$332.00K 10-Q · filed 2022-11-07 | -$800.00K derived: sum of 2 quarters · filed 2022-11-07 | -$1.28M 10-Q · filed 2022-11-07 | -$1.79M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$468.00K 10-Q · filed 2022-08-08 | -$950.00K 10-Q · filed 2022-08-08 | -$1.46M derived: sum of 3 quarters · filed 2022-08-08 | -$1.99M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$482.00K 10-Q · filed 2022-05-10 | -$995.00K derived: sum of 2 quarters · filed 2022-05-10 | -$1.52M derived: sum of 3 quarters · filed 2022-05-10 | -$1.86M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$1.04M derived: sum of 2 quarters · filed 2022-03-15 | -$1.37M derived: sum of 3 quarters · filed 2022-03-15 | -$1.52M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$526.00K 10-Q · filed 2021-11-10 | -$861.00K derived: sum of 2 quarters · filed 2021-11-10 | -$1.01M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$335.00K 10-Q · filed 2021-09-09 | -$483.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |